Viewing Study NCT04688151


Ignite Creation Date: 2025-12-24 @ 11:53 PM
Ignite Modification Date: 2026-01-10 @ 2:48 PM
Study NCT ID: NCT04688151
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-05-22
First Post: 2020-12-08
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma.
Sponsor: National Health Research Institutes, Taiwan
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module